David Scott Jones - 09 Feb 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2023
Net transactions value
-$12,327
Form type
4
Filing time
13 Feb 2023, 16:02:39 UTC
Previous filing
10 Jan 2023
Next filing
22 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +4,967 +27% $0.000000 23,089 09 Feb 2023 Direct F1
transaction EYPT Common Stock Options Exercise $0 +5,000 +22% $0.000000 28,089 09 Feb 2023 Direct
transaction EYPT Common Stock Tax liability $6,184 -1,483 -5.3% $4.17 26,606 09 Feb 2023 Direct F2
transaction EYPT Common Stock Tax liability $6,142 -1,473 -5.5% $4.17 25,133 09 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -5,000 -33% $0.000000 10,000 09 Feb 2023 Common Stock 5,000 $0.000000 Direct F3
transaction EYPT Restricted Stock Units Options Exercise $0 -4,967 -50% $0.000000 4,967 09 Feb 2023 Common Stock 4,967 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 825 shares acquired on July 31, 2022 and 1,698 shares acquired on January 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.
F3 The restricted stock units vest in three annual installments beginning February 9, 2023.
F4 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.